|
Adjuvant Treatment for Resected Lung Cancer
Untitled Document
Name of the Trial
Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab
in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
(ECOG-E1505). See the protocol
summary.
Principal Investigators
 |
Dr. Heather Wakelee
Principal Investigator |
Dr. Heather Wakelee, Dr. Alan Sandler, and Dr. Steven Keller, ECOG;
Dr. David Gandara and Dr. Eric Vallieres, SWOG;
Dr. Stephen Graziano and Dr. Richard Battafarano, CALGB;
Dr. Charles Butts, NCIC-Clinical
Trials Group; and Dr. Alex Adjei, NCCTG.
Why This Trial Is Important
More Americans die each year from lung cancer than from breast, colon, and
prostate cancer combined. Although surgery can be curative, many patients will
experience a relapse and eventually die from their disease. Consequently, doctors
often give chemotherapy after surgery (adjuvant chemotherapy) in an attempt
to kill any remaining cancer cells.
The addition of the monoclonal antibody bevacizumab (Avastin) to chemotherapy
has helped extend the lives of some patients with inoperable advanced or metastatic
non-small cell lung cancer (NSCLC). Now doctors are interested in determining
whether the addition of bevacizumab to adjuvant chemotherapy can help patients
with early NSCLC live longer following surgery to remove their tumors.
Bevacizumab blocks the activity of a protein called vascular endothelial growth
factor (VEGF), which promotes the growth of blood vessels (angiogenesis) to
tumors. Angiogenesis is essential for tumors to get the oxygen and nutrients
they need to grow bigger than a few millimeters.
"Bevacizumab in addition to chemotherapy is proven to help people with
advanced lung cancer live longer," said Dr. Wakelee. "Because of the
way this agent works, we're hopeful that giving it along with chemotherapy to
patients with completely resected early-stage lung cancer will help block the
development of advanced disease and possibly produce a cure for some of these
patients."
Who Can Join This Trial
Researchers seek to enroll 1,500 adult patients with stage IB-IIIA NSCLC that
has been completely removed by surgery. See the list
of eligibility criteria.
Study Sites and Contact Information
Study sites in the United States are recruiting patients for this trial. See
the list
of study contacts or call the NCI's Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237) for more information. The toll-free call is confidential.
Back to Top |
